8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 4, 2018

REVANCE THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

DELAWARE	001-36297	75-0551645
(State of incorporation)	(Commission File No.)	(IRS Employer Identification No.)

Revance Therapeutics, Inc.

7555 Gateway Boulevard

Newark, California 94560

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (510) 742-3400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

On December 4, 2018, Revance Therapeutics, Inc. (“Revance” or “the Company”) and Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd (“Fosun”), entered into a license agreement (the “Agreement”) pursuant to which Revance has granted Fosun the exclusive rights to develop and commercialize the Company’s proprietary DaxibotulinumtoxinA for Injection (RT002) (the “Product”) in mainland China, Hong Kong and Macau (the “Territory”) and certain sublicense rights.

Under the Agreement, Revance will receive a non-refundable upfront payment of $30 million within thirty (30) business days of the date of the Agreement and is eligible to receive (i) additional contingent payments of up to $230.5 million upon the achievement of specified milestones based on (a) the submission and approval of Biologics License Applications (“BLAs”) for certain aesthetic and therapeutic indications and (b) first time calendar year net sales, and (ii) tiered royalty payments in low double digit to high teen percentages on annual net sales. The royalty percentages are subject to reduction in the event that (i) the Company does not have any valid and unexpired patent claims that cover the Product in the Territory, (ii) biosimilars of the Product are sold in the Territory or (iii) Fosun needs to pay compensation to third parties for Fosun to either avoid patent infringement or market the Product in the Territory.

Under the Agreement, Fosun will have the right to import, develop, commercialize, market and sell the Product in the Territory or engage service providers for such activities, and Revance will be responsible for manufacturing the Product and supplying it to Fosun for its clinical and commercial activities in the Territory, subject to the terms of a supply agreement and a quality assurance agreement, each to be entered into between the parties in the six (6) months following the date of the Agreement. Except as provided in the Agreement, each party has retained all of its intellectual property rights.

During the term of the Agreement and an additional two (2) years from the termination date if Fosun terminates the Agreement, Fosun will not engage in any research, development, manufacture or commercialization of any product competitive with the Product; provided that such non-compete restrictions will expire if Revance fails to submit a BLA for the Product in the US by the end of 2020. Under the Agreement, Revance and Fosun will also establish a joint development committee, which will oversee the development and commercialization of the Product as well as all clinical and pre-clinical studies to be conducted by Fosun for the Product in the Territory.

The term of the Agreement will continue until Fosun’s payment obligations have been performed or expired, unless sooner terminated by either party pursuant to the terms of the Agreement. Either party may terminate the Agreement for material breach by, or bankruptcy of, the other party. In addition, Revance may terminate the Agreement if Fosun challenges Revance’s patents, and Fosun may terminate the Agreement upon one hundred twenty (120) days notice. In the event of a change of control of Revance, Revance or its successor will have the option to terminate the Agreement by paying Fosun a variable payment that depends on the stage of development of the Product.

The Agreement contains various representations and warranties, covenants and other provisions that are customary for a transaction of this nature. The representations, warranties and covenants contained in the Agreement were made only for purposes of the Agreement and as of specific dates, were solely for the benefit of the parties to the Agreement, and may be subject to limitations agreed upon by the parties. The representations and warranties may have been made for the purposes of allocating contractual risk between the parties to the Agreement instead of establishing these matters as facts.

The foregoing is a summary of the terms of the Agreement and is qualified in its entirety by reference to the Agreement, a copy of which will be filed as an exhibit to the Company’s Annual Report on Form 10-K for the fiscal year ending December 31, 2018.

ITEM 7.01 REGULATION FD DISCLOSURE

The Company issued a press release on December 4, 2018, announcing clinical results from its SAKURA 3 Phase 3 trials of DaxibotulinumtoxinA for Injection (RT002) for the treatment of glabellar (frown) lines. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

During a conference call and webcast scheduled to be held at 5:30 a.m. Pacific Time on December 4, 2018, Company management will discuss the results from the study. The slide presentation for the conference call and webcast is furnished as Exhibit 99.2 hereto and is incorporated by reference herein.

The information in this Item 7.01 of this current report on Form 8-K and Exhibits 99.1 and 99.2 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

ITEM 8.01 OTHER EVENTS

RT002 – Glabellar Lines

On December 4, 2018, the Company announced its long-acting neuromodulator DaxibotulinumtoxinA for Injection (RT002) with its proprietary stabilizing excipient peptide technology delivered positive top-line results in alleviating moderate-to-severe glabellar (frown) lines in the SAKURA 3 Phase 3 open-label, long-term safety study:

SAFETY

RT002 appeared to be generally well-tolerated, with no new tolerability or safety concerns reported. As was seen in the SAKURA 1 and SAKURA 2 pivotal trials, adverse events were mild, localized and transient. The rate of treatment-related adverse events decreased over successive treatments. The most common treatment-related adverse events per treatment of RT002 were headache (3.3 percent of treatments), injection site pain (2.7 percent) and injection site erythema (2.5 percent). There were no treatment-related serious adverse events. Eyelid ptosis was reported in 0.9 percent of treatments, decreased in frequency with successive treatments and was substantially lower than the rate observed in SAKURA 1 and SAKURA 2 (2.2 percent). The majority of ptosis events were characterized as mild in severity (85 percent) and transient.

EFFICACY

A high degree of efficacy was seen consistently across all three treatment cycles. Results were consistent with SAKURA 1 and SAKURA 2 based on the Investigator Global Assessment-Facial Wrinkle Severity (IGA-FWS) and Patient Facial Wrinkle Severity (PFWS) scales. As early as Week 1, over 90 percent of subjects across all three treatments had none or mild wrinkles.

At Week 4, the none or mild response rates as assessed by IGA-FWS were:

• SAKURA 3: First treatment 95.8 percent; second treatment 96.6 percent; third treatment 97.7 percent

• SAKURA 1: 97.5 percent

• SAKURA 2: 97.5 percent

On the more stringent 2-point composite endpoint, which was the primary efficacy endpoint in SAKURA 1 and 2, efficacy improved with successive treatment cycles:

• SAKURA 3: First treatment 73.2 percent; second treatment 77.7 percent; third treatment 79.6 percent

• SAKURA 1: 73.6 percent

• SAKURA 2: 74.0 percent

DURATION

As in the SAKURA 1 and SAKURA 2 pivotal trials, there were several secondary endpoints used to evaluate duration of effect, including median time to loss of none or mild wrinkle severity on both IGA-FWS and PFWS, and median duration for time to return to baseline wrinkle severity on both IGA-FWS and PFWS. Duration was evaluated in the first two 36-week treatment cycles; the third treatment cycle was not evaluated for duration as the observation period ended at twelve weeks for the purpose of this study.

Median time to return to baseline wrinkle severity on both IGA-FWS and PFWS:

• SAKURA 3: First treatment 28.0 weeks; second treatment 28.1 weeks

• SAKURA 1: 27.7 weeks

• SAKURA 2: 26.0 weeks

Median time to loss of none or mild wrinkle severity on both IGA-FWS and PFWS:

• SAKURA 3: First treatment 24.0 weeks; second treatment 24.1 weeks

• SAKURA 1: 24.0 weeks

• SAKURA 2: 23.9 weeks

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

Exhibit Number	Description
99.1	Press Release dated December 4, 2018
99.2	Revance Therapeutics, Inc. Investor Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 4, 2018	Revance Therapeutics, Inc.
	By:	/s/ Caryn G. McDowell
		Caryn G. McDowell
		Senior Vice President, General Counsel & Corporate Secretary

EX-99.1

Exhibit 99.1

Revance’s RT002 Demonstrates Unprecedented Efficacy and Duration

In Largest-Ever Aesthetic Neuromodulator Clinical Program

– In SAKURA 3, RT002 was well-tolerated across over 3,800 treatments in glabellar (frown) lines –

– The median time to return to baseline glabellar line severity was 28 weeks –

– RT002 represents the first long-acting neuromodulator, allowing for two or fewer treatments per year –

– Revance announces new trials in forehead lines and lateral canthal lines (crow’s feet) –

– Revance to host conference call at 8:30 am ET today –

NEWARK, Calif., December 4, 2018 - Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced its long-acting neuromodulator DaxibotulinumtoxinA for Injection (RT002) with its proprietary stabilizing excipient peptide technology delivered positive top-line results in alleviating moderate-to-severe glabellar (frown) lines in the SAKURA 3 Phase 3 open-label, long-term safety study. Completion of this study paves the way for Revance to submit a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA), which is on-track for the first half of 2019.

As a component of the largest clinical program of an aesthetic neuromodulator, the SAKURA 3 study included nearly 2,700 patients and more than 3,800 treatments. Patients received up to three treatments of RT002 and were followed for over a year and a half. Overall, the safety findings were consistent with the known safety profiles for currently available neuromodulators in aesthetics. Importantly, the rate of treatment-related adverse events decreased over successive treatments. For efficacy, based on investigator assessment, more than 95% of patients achieved a score of none or mild glabellar lines at maximum frown at Week 4 after each of three treatments. Measuring duration of effect, the median time to return to baseline glabellar line severity was 28 weeks. The median time to loss of none or mild wrinkle severity was 24 weeks. The SAKURA 3 results were consistent with those in the Phase 3 pivotal trials, SAKURA 1 and SAKURA 2.

“The results of this trial are exceptional since they demonstrate that RT002 has consistently and predictably produced long duration and high response rates and was well tolerated over successive treatments,” said SAKURA investigator Jean D. Carruthers, M.D., who has served as an investigator for multiple FDA-approved neuromodulators, and is a clinical professor at the University of British Columbia. “My study patients were thrilled with their appearance and the longevity RT002 delivered, and they can’t wait for this treatment option. I look forward to the possibility of providing my patients a new, unique neuromodulator that needs just two or fewer treatments a year.”

Dan Browne, co-founder, president and chief executive officer of Revance said, “We are very excited by these compelling new data, which support RT002 as a next-generation neuromodulator with highly differentiated characteristics. We look forward to working closely with the FDA to bring this important treatment to patients as soon as possible. The success of the SAKURA aesthetic trials, combined with our ongoing therapeutic studies in multiple neuroscience indications, drive our mission to become the leading innovator in neuromodulators.”

Following these results, Revance today announced it will begin studies in 2019 in forehead and lateral canthal lines (crow’s feet) to explore the use and dosage of RT002 in the upper face.

“The long-term results in these studies, which are consistent and predictable across age groups and prior toxin experience, are extremely impressive,” said SAKURA investigator Steven Fagien, M.D., FACS, Aesthetic Eyelid Plastic Surgery, Boca Raton, Florida, and one of the world’s foremost experts in injectable neuromodulators. “The SAKURA data demonstrate RT002 provides a trifecta of results – a reassuring safety profile, high patient response rates, and long-lasting results. RT002 has the potential to raise the bar of expectations for neuromodulators in the injectable facial aesthetic landscape.”

Global sales of neuromodulators totaled $4 billion in 2017 and are estimated to nearly double by 2025. Despite this, market penetration has remained below 10 percent for decades, at least in part because currently available short-acting neuromodulators do not address the number one desire of patients and physicians for longer-lasting results.

According to findings from a proprietary landmark survey of more than 2,000 women aged 25-70 conducted on behalf of Revance by The Harris Poll,* facial lines and wrinkles are the most concerning visible sign of aging among women in this age range. Still, only seven percent of women said they have used a neuromodulator in the past five years. In addition, the survey also included 246 dermatologists and plastic surgeons who see at least 15 patients a week who receive neuromodulator treatments. Among this group of physicians, 86 percent wish there was a neuromodulator that offered longer-lasting results than what is currently available.

SAKURA 3 TOP-LINE RESULTS

The SAKURA program targeted enrollment of at least 2,600 patients to receive at least one treatment and 500 to receive three treatments with RT002. The topline results include data from 2,691 subjects with moderate-to-severe glabellar lines who were treated with RT002 (40U); 2,380 patients received Treatment #1, 882 patients received Treatment #2, and 568 patients received all three treatments. In general, results across safety, efficacy and duration measures were consistent and predictable across age groups and prior toxin experience.

SAFETY

RT002 appeared to be generally well-tolerated, with no new tolerability or safety concerns reported. As was seen in the SAKURA 1 and SAKURA 2 pivotal trials, adverse events were mild, localized and transient. The rate of treatment-related adverse events decreased over successive treatments. The most common treatment-related adverse events per treatment of RT002 were headache (3.3 percent of treatments), injection site pain (2.7 percent) and injection site erythema (2.5 percent). There were no treatment-related serious adverse events. Eyelid ptosis was reported in 0.9 percent of treatments, decreased in frequency with successive treatments and was substantially lower than the rate observed in SAKURA 1 and SAKURA 2 (2.2 percent). The majority of ptosis events were characterized as mild in severity (85 percent) and transient.

EFFICACY

A high degree of efficacy was seen consistently across all three treatment cycles. Results were consistent with SAKURA 1 and SAKURA 2 based on the Investigator Global Assessment-Facial Wrinkle Severity (IGA-FWS) and Patient Facial Wrinkle Severity (PFWS) scales. As early as Week 1, over 90 percent of subjects across all three treatments had none or mild wrinkles.

At Week 4, the none or mild response rates as assessed by IGA-FWS were:

• SAKURA 3: First treatment 95.8 percent; second treatment 96.6 percent; third treatment 97.7 percent

• SAKURA 1: 97.5 percent

• SAKURA 2: 97.5 percent

On the more stringent 2-point composite endpoint, which was the primary efficacy endpoint in SAKURA 1 and 2, efficacy improved with successive treatment cycles:

• SAKURA 3: First treatment 73.2 percent; second treatment 77.7 percent; third treatment 79.6 percent

• SAKURA 1: 73.6 percent

• SAKURA 2: 74.0 percent

DURATION

As in the SAKURA 1 and SAKURA 2 pivotal trials, there were several secondary endpoints used to evaluate duration of effect, including median time to loss of none or mild wrinkle severity on both IGA-FWS and PFWS, and median duration for time to return to baseline wrinkle severity on both IGA-FWS and PFWS. Duration was evaluated in the first two 36-week treatment cycles; the third treatment cycle was not evaluated for duration as the observation period ended at twelve weeks for the purpose of this study.

Median time to return to baseline wrinkle severity on both IGA-FWS and PFWS:

• SAKURA 3: First treatment 28.0 weeks; second treatment 28.1 weeks

• SAKURA 1: 27.7 weeks

• SAKURA 2: 26.0 weeks

Median time to loss of none or mild wrinkle severity on both IGA-FWS and PFWS:

• SAKURA 3: First treatment 24.0 weeks; second treatment 24.1 weeks

• SAKURA 1: 24.0 weeks

• SAKURA 2: 23.9 weeks

About SAKURA Phase 3 Clinical Program

The SAKURA Phase 3 clinical program is the largest-ever aesthetic neuromodulator clinical program, including nearly 2,800 patients who received, in total, more than 4,200 treatments with RT002.

The SAKURA program included SAKURA 1 and SAKURA 2 – two randomized, double-blind, placebo-controlled pivotal trials that were identical in design to evaluate the safety and efficacy of a single administration of RT002 for the treatment of moderate-to-severe glabellar lines in adults from 18 to 75 years of age —and SAKURA 3, an open-label trial designed to evaluate the long-term safety of RT002 in glabellar lines following both single and repeat treatment administration in adults 18 years and older. The SAKURA 1 and SAKURA 2 trials enrolled a total of 609 patients at 30 sites in the U.S. and Canada. In these trials, patients were randomized 2:1 to receive either RT002 (40U) or placebo. Post-treatment, patients were followed for at least 24 weeks, at which time they were eligible to roll-over into SAKURA 3.

The SAKURA 3 long-term safety trial enrolled 2,691 patients at 66 sites in the U.S. and Canada. In SAKURA 3, patients were eligible to receive up to three treatments and were followed for up to 84 weeks. Subjects were eligible to be followed for up to 36 weeks after both treatments 1 and 2 and for up to 12 weeks after treatment 3.

About Glabellar Lines

The glabella is the area between the eyebrows and above the nose. Glabellar lines, often called “frown lines,” are vertical lines that develop between the eyebrows and may appear as a single vertical line or as two or more lines. When you frown, the muscles of the glabella contract causing vertical creases to form between the eyebrows. Botulinum toxin is used to temporarily block the ability of nerves to trigger contraction of injected muscle, inhibiting movement of the muscles that cause the frown lines, giving the skin a smoother, more refreshed appearance.

Based on data from Global Industry Analysts, Inc., the global market for aesthetic treatments with neuromodulators represented about $1.6 billion in revenue in 2016, and according to the American Society for Aesthetic Plastic Surgery, botulinum toxin treatment is the No.1 nonsurgical cosmetic procedure in the U.S. Management estimates glabellar line treatment represents nearly $1 billion of the global market.

About RT002

DaxibotulinumtoxinA for Injection (RT002) is an investigational product and the first neuromodulator with long-lasting duration. It is a novel, next-generation neuromodulator in development for the treatment of aesthetic indications and a number of potential therapeutic conditions, including movement disorders, pain and other neuroscience-based targets. RT002 is the only neuromodulator using a Revance proprietary stabilizing excipient peptide technology in its formulation, which results in high efficacy, long duration and provides two-year product stability requiring no refrigeration. RT002 is the first and only botulinum toxin product sourced, processed and manufactured in the U.S. and formulated without human blood-derived products or manufactured using animal-derived proteins.

Revance has four active clinical programs for RT002 injectable under way. The SAKURA 1, SAKURA 2 and SAKURA 3 trials to treat glabellar lines are complete. For cervical dystonia, the company was granted orphan drug designation from the FDA and initiated a Phase 3 program in mid-2018. The company plans to announce first patient dosing for Phase 2 trials for RT002 for the management of plantar fasciitis and for adult upper limb spasticity before year-end 2018.

Conference Call

Individuals interested in listening to the conference call may do so by dialing (855) 453-3827 for domestic callers, or (484) 756-4301 for international callers and reference conference ID: 2281019; or from the webcast link in the investor relations section of the company’s website at: www.revance.com.

A replay of the call will be available beginning December 4, 2018 at 8:30am PT/11:30am ET to December 5, 2018 at 8:30am PT/11:30am ET. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference conference ID: 2281019. The webcast will be available in the investor relations section on the company’s website for 30 days following the completion of the call.

About Revance Therapeutics, Inc.

Revance Therapeutics is an emerging Silicon Valley biotechnology leader developing neuromodulators for the treatment of aesthetic and therapeutic conditions. Revance uses a unique proprietary, stabilizing excipient peptide technology to create novel, differentiated therapies. The company’s lead compound, DaxibotulinumtoxinA for Injection (RT002), is in clinical development for a broad range of aesthetic and therapeutic indications, including glabellar lines, cervical dystonia, plantar fasciitis, upper limb spasticity and chronic migraine. RT002 has the potential to be the first long-acting neuromodulator. The company is advancing a robust pipeline of injectable and topical formulations of daxibotulinumtoxinA. More information on Revance may be found at www.revance.com.

“Revance Therapeutics” and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

*Method Statement -This survey was conducted online by The Harris Poll on behalf of Revance among women aged 25-70 and Dermatologists and Plastic Surgeons who see patients who receive neuromodulator treatments in the United States. The consumer survey was conducted July 11 through July 30, 2018 among 1,004 women ages 25-70 who have used a Neuromodulator in the past 5 years and 1,005 women ages 25-70 who have either never used a Neuromodulator, or have used one 5+ years ago. Figures for age by gender, education, income, race/ethnicity, region, size of household, marital status, and employment status were weighted where necessary to bring them into line with their actual proportions in the population. The healthcare professional survey was conducted July 31 through August 29, 2018 among 141 Dermatologists and 105 Plastic Surgeons who see at least 15 patients per week who receive a Neuromodulator treatment. Results were weighted for gender by years in practice and region where necessary to bring them into line with their actual proportions in the population.

Forward-Looking Statements

This press release contains forward-looking statements, including statements related to Revance Therapeutics’ current and anticipated future clinical development of our investigational drug product candidates, the initiation, design, timing and results of our clinical studies, including the SAKURA 3 study of RT002, and related reporting of such results; the timing for the Phase 2 trials for RT002 for the management of plantar fasciitis and for adult upper limb spasticity; statements about our business strategy, timeline and other goals and market for our anticipated products, plans and prospects; including our pre-commercialization plans and timing of our potential BLA submission for RT002 to treat glabellar (frown) lines and commercial potential of our client candidates; and statements about our ability to obtain regulatory approval with respect to our drug; and potential benefits of our drug product candidates and our excipient peptide and other technologies.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties include, but are not limited to: the outcome, cost, and timing of our product development activities and clinical trials; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results, or that positive results would assure regulatory approval or commercial success of our product candidates; our ability to obtain and maintain regulatory approval of our drug product candidates; our ability to obtain funding for our operations; our plans to research, develop, and commercialize our drug product candidates; our ability to achieve market acceptance of our drug product candidates; unanticipated costs or delays in research, development, and commercialization efforts;

the applicability of clinical study results to actual outcomes; the size and growth potential of the markets for our drug product candidates; our ability to successfully commercialize our drug product candidates and the timing of commercialization activities; the rate and degree of market acceptance of our drug product candidates; our ability to develop sales and marketing capabilities; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; and other risks. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Revance’s periodic filings with the Securities and Exchange Commission (the “SEC”), including factors described in the section entitled “Risk Factors” of our quarterly report on Form 10-Q filed November 2, 2018. These forward-looking statements speak only as of the date hereof. Revance disclaims any obligation to update these forward-looking statements.

###

Contacts

INVESTORS

Revance Therapeutics, Inc.:

Jeanie Herbert

(714) 325-3584

jherbert@revance.com

or

Burns McClellan, Inc.:

Ami Bavishi

(212) 213-0006

abavishi@burnsmc.com

MEDIA

General Media:

TOGORUN:

Mariann Caprino

(917) 242-1087

m.caprino@togorun.com

or

Trade Media:

Nadine Tosk

(504) 453-8344

nadinepr@gmail.com

Source: Revance Therapeutics, Inc.

EX-99.2

SAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the  Treatment of Moderate to Severe Glabellar Lines   Topline Results Presented by Dan Browne, Co-Founder, President & CEO, and Roman G. Rubio, MD, Senior Vice President of Clinical Development 4 December 2018 Exhibit 99.2

Forward-Looking Statements / Safe Harbor / Market Data “Revance Therapeutics”, TransMTS, “Remarkable Science. Enduring Performance”, and the Revance logo are registered trademarks of Revance Therapeutics, Inc. All other trademarks or registered trademarks are the property of their respective owners.This presentation contains forward-looking statements, including statements related to: the process and timing of anticipated future clinical development of our product candidates; our business strategy, goals, plans and prospects; timing and outcome of our clinical trials, including the SAKURA 3 study of RT002; timing of our potential BLA submission for RT002 to treat glabellar (frown) lines and commercial potential of our client candidates, potential receipt of milestones and royalties on potential future sales of RT002 under the license with Fosun Pharma; our ability to obtain regulatory approval; the potential therapeutic and economic benefits and value of our product candidates and our technologies; demand for our product candidates and drivers of demand; market size, adoption rate and potential revenue; growth opportunities and product pipeline; our business strategy, timeline and other goals and market for our anticipated products, plans and prospects; our ability to leverage our investment in our development and manufacturing platform; and our intellectual property strategy. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties include, but are not limited to: the outcome, cost and timing of our product development activities and clinical trials; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results, or that positive results would assure regulatory approval or commercial success of our product candidates; that we may not obtain the anticipated financial and other benefits of the license agreement with Fosun Pharma; our ability to obtain and maintain regulatory approval of our product candidates; our ability to obtain funding for our operations; our plans to research, develop and commercialize our product candidates; our ability to achieve market acceptance of our product candidates; unanticipated costs or delays in research, development and commercialization efforts the size and growth potential of the markets for our product candidates; our ability to successfully commercialize our product candidates and the timing of commercialization activities; the rate and degree of market acceptance of our product candidates; our ability to develop sales and marketing capabilities; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; and our ability to continue obtaining and maintaining intellectual property protection for our product candidates. These and other risks are described in the “Risk Factors” section of our Form 10-Q filed with the Securities and Exchange Commission on November 2, 2018. This presentation also includes information about the global neuromodulator market, including growth and trends, that is based on various publicly available sources and on a number of assumptions and limitations. The industry data and third-party overview included in this presentation have been obtained from sources believed to be reliable, but we have not independently verified such information and assume no responsibility for the accuracy of such information. In addition, projections, assumptions and estimates of the future performance of the global neuromodulator market are necessary subject to a higher degree of uncertainty and risk due to a variety of factors, including those described above and in the “Risk Factors” section of our Form 10-Q filed with the Securities and Exchange Commission on November 2, 2018. The “Risk Factors” section of our Form 10-Q speaks only as of the date thereof. The forward-looking statements and market data in this presentation speak only as of the date hereof or the date specified. Revance disclaims any obligation to update such forward-looking statements and also disclaims any obligation to update or correct such market data.

Fosun Group is one of China’s largest private industrial and investment conglomerates Upfront: $30M Total milestones: $200M+ Tiered royalties: low-double-digit up to high-teens There will be no transfer of intellectual property Fosun Pharma has exclusive rights to develop, commercialize & distribute RT002 in the territory Conduct and fund clinical studies necessary for regulatory approval of RT002 in the territory Revance will supply finished drug product for both the clinical and commercial activities Licensing Agreement - Ideal Partnership for RT002 in China, Hong Kong and Macau for all potential aesthetic and therapeutic indications

SAKURA 3 Open-Label Safety Study Top-Line Results with RT002 in Glabellar Lines Completion of the largest-ever aesthetic neuromodulator clinical program paves the way for BLA filing 1H 2019 SAFETY – Well-tolerated across 3,800 treatments in glabellar (frown) lines Adverse events were mild, localized and transient Rate of treatment related AEs decreased over successive treatments Eyelid Ptosis rate less than 1% per treatment EFFICACY – Greater than 95% response rate at Week 4 (by investigator) Greater than 90% response at Week 1 (by investigator) Efficacy exceeded or was comparable to that seen in SAKURA 1 & 2 DURATION – Median time to return to baseline was 28 weeks Results demonstrated consistency across treatment cycles CONSISTENCY – Safety, efficacy and duration exceeded or was comparable to that seen in SAKURA 1 & 2 Safety profile consistent with SAKURA 1 & 2 and other approved neuromodulators Extended duration of effect across all treatment groups; including age and toxin treatment experience

Open-Label Phase 3 Safety Study Results Presented by Roman G. Rubio, MD Senior Vice President of Clinical Development

SAKURA Clinical Trial – Largest-Ever Aesthetic Neuromodulator Clinical Program *U.S. only **U.S. and Canada SAKURA 1 Pivotal: 36 Weeks N = 303 Treatment Centers: 15* DAXI 201 Placebo 102 SAKURA 3 Open-Label, Long-term Safety: 84 Weeks Total: Over 2,800 patients received more than 4,200 DAXI 40U treatments across Phase 1 – 3 GL program SAKURA 2 Pivotal: 36 Weeks N = 306 Treatment Centers: 15** DAXI204 Placebo 102 DAXI Treatment Cycle 1 (36 wks) DAXI Treatment Cycle 2 (36 wks) DAXI Treatment Cycle 3 (12 wks) N = 2,691 Treatment Centers: 66** 2,380 882 568 Total Number of DAXI Treatment Cycles 3,830

Study Objective and Endpoints 1 Safety evaluable population includes all subjects exposed to the investigational product 2 Conducted for overall trial summary and by treatment period Study Objective: To evaluate the long-term safety of DaxibotulinumtoxinA for Injection (RT002) for the treatment of moderate-to-severe glabellar lines following single and repeat administration Safety Endpoints1 Incidence, severity and relationship to trial drug of: Treatment-emergent adverse events during each treatment and the trial overall Treatment-emergent serious adverse events during each treatment and the trial overall Key Effectiveness Endpoints2 Proportion of subjects with a score of 0 or 1 (None or Mild) as evaluated by IGA-FWS and PFWS over time Proportion of subjects with a ≥2 point improvement from baseline on both IGA-FWS and PFWS over time Time to loss of None or Mild on both IGA-FWS and PFWS Time to return to, or worse than, baseline on both IGA-FWS and PFWS Proportion of subjects with a ≥1 point improvement on GAIS as evaluated by investigator and subject over time

SAKURA 1 and 2 Study Designs Two Pivotal Phase 3 Studies identical in design (total N = 609) evaluating the Efficacy and Safety of DaxibotulinumtoxinA for Injection over 36 Weeks for the Treatment of Moderate-to-Severe Glabellar Lines at 30 sites across U.S. and Canada N=303 2:1 Randomization Week 0 1 2 4 24 36 Primary Endpoint Single Administration Last Mandatory Visit † Final Visit DaxibotulinumtoxinA 40U (n=201) Placebo (n=102) N=306 2:1 Randomization DaxibotulinumtoxinA 40U (n=204) Placebo (n=102) SAKURA 1 SAKURA 2 Visit every 4 weeks Visit every 4 weeks †Subjects eligible for retreatment beginning at Week 24 when both IGA-FWS and PFWS return to baseline

SAKURA 3 Open-Label Safety (OLS) Study Design A prospective, 84 week Open-Label, Repeat Dose Study evaluating the Safety and Effectiveness of DaxibotulinumtoxinA for Injection to Treat Moderate-to-Severe Glabellar Lines conducted at 66 sites across U.S. and Canada DAXI 40U Treatment 3 DAXI 40U Treatment 1 De Novo Subjects SAKURA 1 and 2 Subjects 36 Week Follow up † 36 Week Follow up † 12 Week Follow up Eligible Number of Treatments in OLS 2 1 3 Single Rx Group Multiple Rx Group DAXI 40U Treatment 2 †Subjects eligible for retreatment beginning at Week 12 when both IGA-FWS and PFWS return to baseline SAKURA 3 Open-Label Safety Study Subjects evaluated at Baseline, Weeks 1, 2, 4 and every 4 weeks through Week 36 for treatment cycle 1 and 2, and through Week 12 for treatment cycle 3 N = 477 N = 556 N = 1,658 Total N = 2,691

Frown Wrinkle Severity Scales Both investigators and subjects trained at trial initiation on a validated 4-point Wrinkle Severity Scale to assess severity of glabellar frown lines At entry, subjects were required to have glabellar line wrinkle severity of either Moderate or Severe as assessed by both investigator and subject Utilized across SAKURA 1, 2 and 3 Studies IGA-FWS Rating Score Frown Wrinkle Severity 0 None 1 Mild 2 Moderate 3 Severe PFWS Rating Score Frown Wrinkle Severity Description 0 None No wrinkles 1 Mild Very shallow wrinkles 2 Moderate Moderate wrinkles 3 Severe Deep wrinkles Investigator Global Assessment-Frown Wrinkle Severity (IGA-FWS) Scale Patient Frown Wrinkle Severity (PFWS) Scale

Disposition N (%) Number of Subjects Enrolled 2,691 Number of Subjects who Completed Study 2,314 (86.0%) Number of Subjects who Discontinued Study 377 (14.0%) Reasons for Discontinuation Withdrawal by Subject 196 (7.3%) Lost to Follow up 99 (3.7%) Protocol Deviation 53 (2.0%) Other 15 (0.6%) Investigator Discretion 8 (0.3%) Adverse Event 5 (0.2%) Death* 1 (0.04%) Subject Disposition SAKURA 3 OLS had high completion rate across treatment cycles *Secondary to Homicide

Total in SAKURA 3 Number of Subjects 2,691 DAXI 40U Treatment Received in OLS Treatment Cycle #1 2,380 Treatment Cycle #2 882 Treatment Cycle #3 568 Total Number of Treatments 3,830 Subject Disposition SAKURA 3 OLS enrolled nearly 2,700 subjects to fulfill FDA requirement of at least 2,100 single treatments and 500 triple treatments

Demographics SAKURA 1 & 2 DAXI Pooled (N=405) SAKURA 3 OLS (N=2691) Female, n (%) 357 (88.1%) 2383 (88.6%) Age (years), mean (SD) range [min, max] 50.2 (1.46) [21, 74] 49.5 (11.27) [21, 86] Race White 353 (87.2%) 2407 (89.4%) Black/African American 19 (4.7%) 129 (4.8%) Asian 18 (4.4%) 73 (2.7%) Other 15 (3.7%) 82 (3.0%) Ethnicity Hispanic/Latino 66 (16.2%) 516 (19.2%) Not Hispanic/Latino 339 (83.5%) 2175 (80.8%) The SAKURA program evaluated a diverse Treatment Population with DAXI across all 3 Phase 3 studies

Baseline Characteristics SAKURA 1 & 2 DAXI Pooled (N=405) SAKURA 3 OLS (N=2691) Prior BoNT-A*, n (%) 213 (52.6) 1074 (39.9%) Months since last BoNT-A* mean (SD) range 27.4 (1.59) [7, 205] 34.9 (41.78) [0.2, 320] PFWS at Maximum Frown Moderate 226 (55.8) 1482 (55.1%) Severe 179 (44.2%) 1208 (44.9%) IGA-FWS at Maximum Frown Moderate 252 (62.2%) 1652 (61.4%) Severe 153 (37.8%) 1039 (38.6%) *Botulinum toxin type A SAKURA 3 OLS enrolled both BoNT-A* treatment-experienced and BoNT-A treatment-naïve subjects to reflect real world treatment population

Summary of Adverse Events Regardless of Causality SAKURA 3 OLS Compared with SAKURA 1 and 2 SAKURA 1 & 2 DAXI Pooled (N=406) n (%) SAKURA 3 OLS (N=2691) n (%) Death* 0 1 (<0.1%) Serious AEs (SAE) 4 (1.0%) 29 (1.1%) Subjects with any AE 166 (40.9) 1043 (38.8%) Mild 124 (30.5%) 739 (27.5%) Moderate 36 (8.9%) 267 (9.9%) Severe 6 (1.5%) 37 (1.4%) Subjects with any AE leading to Study Discontinuation 0 5 (0.2%) Treatment-Related Adverse Events** Subjects with any Treatment-Related AE 78 (19.2%) 480 (17.8%) Treatment-Related SAE 0 0 * Secondary to homicide **Considered by investigator to be possibly, probably or definitely related to the treatment. The Majority of AEs were Mild in Severity with No Treatment-Related SAEs across the SAKURA Program

Adverse Events Regardless of Causality (≥2% in OLS) SAKURA 3 OLS Compared with SAKURA 1 and 2 Preferred Term SAKURA 1 & 2 Pooled (N=406) n (%) SAKURA 3 OLS (N=2691) n (%) Headache 37 (9.1%) 158 (5.9%) Nasopharyngitis 17 (4.2%) 119 (4.4%) Injection site pain 15 (3.7%) 105 (3.9%) Injection site erythema 5 (1.2%) 90 (3.3%) Injection site oedema 5 (1.2%) 76 (2.8%) Erythema 1 (0.2%) 56 (2.1%) Upper respiratory tract infection 11 (2.7%) 55 (2.0%) AEs were uncommon and occurred with a similar frequency in SAKURA 3 as in placebo-controlled SAKURA 1 and 2 studies

Treatment-Related Adverse Events (≥1% in OLS) SAKURA 3 OLS Compared with SAKURA 1 and 2 AE Incidence Rates DAXI 40U Treatments in SAKURA 3 Preferred Term SAKURA 1 & 2 Pooled (N=406) n (%) SAKURA 3 (N=2691) n (%) Treatment Cycle 1 (N=2380) n (%) Treatment Cycle 2 (N=882) n (%) Treatment Cycle 3 (N=568) n (%) All Treatments (N=3830) n (%) Any Treatment-Related AE 78 (19.2%) 480 (17.8%) 400 (16.8%) 86 (9.8%) 40 (7.0%) 526 (13.7%) Headache 26 (6.4%) 124 (4.6%) 102 (4.3%) 13 (1.5%) 12 (2.1%) 127 (3.3%) Injection site pain 15 (3.7%) 98 (3.6%) 81 (3.4%) 18 (2.0%) 7 (1.2%) 106 (2.7%) Injection site erythema 5 (1.2%) 81 (3.0%) 64 (2.7%) 22 (2.5%) 8 (1.4%) 94 (2.5%) Injection site oedema 6 (1.5%) 76 (2.8%) 56 (2.7%) 21 (2.4%) 9 (1.6%) 86 (2.2%) Eyelid ptosis* 9 (2.2%) 34 (1.3%) 23 (1.0%) 7 (0.8%) 4 (0.7%) 34 (0.9%) * 29 (85%) cases mild severity, 5 (15%) cases moderate severity. Median resolution time is 44 days. Treatment-Related Adverse Event Rate was Low and Decreased with Successive Treatments in SAKURA OLS

None or Mild Response Rate over Time on IGA-FWS and PFWS WEEK SAKURA 1 & 2 Pooled (%) n=405 SAKURA 3 Treatment Cycle ONE (%) n=2380 TWO (%) n=882 THREE (%) n=568 1 93.8 91.8 91.5 92.3 2 95.8 96.6 93.9 96.1 4 97.5 95.8 96.6 97.7 8 93.1 91.6 92.2 93.7 12 86.2 81.2 83.9 84.5 16 72.6 67.6 59.4 -- 20 53.8 50.3 45.2 -- 24 32.3 34.0 32.7 -- 28 15.1 22.6 20.9 -- 32 7.7 15.0 10.4 -- 36 4.0 7.3 4.8 -- Investigator Assessment (IGA-FWS) Patient Assessment (PFWS) WEEK SAKURA 1 & 2 Pooled (%) n=405 SAKURA 3 Treatment Cycle ONE (%) n=2380 TWO (%) n=882 THREE (%) n=568 1 86.4 85.1 87.2 88.4 2 91.9 92.0 90.0 92.1 4 91.1 91.6 92.3 93.1 8 84.9 82.4 83.0 85.0 12 72.1 68.4 69.7 74.3 16 55.3 52.5 44.8 -- 20 40.2 36.6 34.8 -- 24 22.7 26.5 22.9 -- 28 11.1 18.5 16.0 -- 32 5.7 12.7 8.5 -- 36 1.7 7.2 3.4 -- Robust Response Rates Observed on Key None or Mild Outcome Measure Maintained Across SAKURA 3 OLS Treatment Cycles

None or Mild Response Rate by IGA-FWS over Time SAKURA 3 OLS Compared with SAKURA 1 and 2 SAKURA 1, 2, and 3 Study Outcomes for None or Mild Response on IGA-FWS Consistent Between Studies and Treatment Cycles

None or Mild Response Rate by PFWS over Time SAKURA 3 OLS Compared with SAKURA 1 and 2 SAKURA 1, 2, and 3 Study Outcomes for None or Mild Response on PFWS Consistent Between Studies and Treatment Cycles

Proportion of Subjects Who Achieve ≥2 Point Composite Response at Max Frown at Week 4 in SAKURA 1, 2, and 3 Two-Point Composite Response Comparable Across Studies and Treatment Cycles SAKURA 1 and 2 SAKURA 3 OLS * p<0.001 vs placebo of 0% (SAKURA 1) and 1% (SAKURA 2)

Time to Loss of None or Mild Wrinkle Severity on Both IGA-FWS and PFWS SAKURA 3 OLS Compared with SAKURA 1 and 2 Data shown include Treatment 1 for OLS Group B (i.e, De Novo + Received Placebo in SAKURA 1 or 2), Treatment 2 for both Groups A and B, and results from SAKURA 1 and 2 studies. Median Duration of 24 Weeks Achieved in SAKURA 3 Treatment Cycles 1 and 2 Confirms Time to Loss of None or Mild Observed in SAKURA 1 and 2

Time to Return to Baseline on Both IGA-FWS and PFWS SAKURA 3 OLS Compared with SAKURA 1 and 2 Data shown are for the first two Treatments of OLS Group B (i.e, De Novo + Received Placebo in SAKURA 1 or 2), and results from SAKURA 1 and 2 studies. Median Duration of 28 Weeks Achieved in SAKURA 3 Treatment Cycles 1 and 2 Confirms Time to Return to Baseline Observed in SAKURA 1 and 2

Investigator and Subject Assessment of Improvement by Study Global Aesthetic Improvement Scale (GAIS)* Both Investigator and Subject Assessment of Improvement (Score ≥ +1) on GAIS Remained Consistently High at Week 4 Across SAKURA 1, 2, and 3 OLS Investigator GAIS Subject GAIS % of Subjects *7-Point Wrinkle Improvement Scale: +3=Very much improved, +2=Much Improved, +1=Improved, 0=No Change, -1=Worse, -2=Much worse, -3=Very much worse

Median Time to Loss of None or Mild on Both IGA-FWS and PFWS by Subgroup No Prior Toxin (n=1617) Prior Toxin (n=1074) All (n=2691) Treatment Duration of 24 Weeks Achieved Regardless of Age and Prior Toxin Experience

Median Time to Return to Baseline on Both IGA-FWS and PFWS by Subgroup No Prior Toxin (n=1617) Prior Toxin (n=1074) All (n=2691) Treatment Duration of 28 Weeks Achieved in <65 yrs Subgroup and Regardless of Prior Toxin Experience, with Duration Extended to 31.4 Weeks in 65 yrs or Older Subgroup

BASELINE Week 16 Week 24 Example 2-Point Improvement by IGA-FWS & PFWS at Week 4 Two Point Sustained Duration of Effect through Week 16 and 1-point Improvement Sustained Through Week 24 in 23 year old Female Week 4 IGA-FWS: 0 PFWS: 0 IGA-FWS: 0 PFWS: 0 IGA-FWS: 1 PFWS: 1 IGA-FWS: 2 PFWS: 2

BASELINE Week 16 Week 24 Example 2-Point Improvement by IGA-FWS & PFWS at Week 4 Week 4 IGA-FWS: 0 PFWS: 0 IGA-FWS: 1 PFWS: 1 IGA-FWS: 1 PFWS: 2 IGA-FWS: 2 PFWS: 2 One Point Improvement Sustained through Week 24 by Investigator Assessment in 44 yo Female

BASELINE Week 16 Week 24 Example 2-Point Improvement by IGA-FWS & PFWS at Week 4 Week 4 IGA-FWS: 0 PFWS: 0 IGA-FWS: 0 PFWS: 1 IGA-FWS: 1 PFWS: 2 IGA-FWS: 2 PFWS: 2 One Point Sustained Duration of Effect through Week 24 by Investigator Assessment in 53 yo Male

Safety Summary – 1 DaxibotulinumtoxinA for Injection SAKURA 3 OLS confirmed the safety profile of DaxibotulinumtoxinA for Injection (DAXI) 40U established in the SAKURA 1 and 2 pivotal studies, with no new tolerability or safety concerns reported, and stable or decreasing rates of AEs following repeat dosing from treatment cycle 1 through treatment cycle 3 A total of 3830 DAXI treatments with DAXI 40U were administered to 2691 subjects in SAKURA OLS No evidence of cumulative AEs over 3 treatment cycles, suggesting the safety profile of DAXI remained stable after repeated dosing Adverse Events (AEs) regardless of causality were experienced in a similar proportion of subjects (39%) in SAKURA 3 OLS, which enrolled 2691 subjects, compared with the placebo-controlled SAKURA 1 and 2 studies (41%) with 406 subjects who received DAXI 40U Majority of AEs were mild in severity with most considered to be unrelated to treatment The most common AEs reported were headache (5.9% subjects), nasopharyngitis (4.4%) and injection site pain (3.9%) Serious AEs occurred at a similar rate in SAKURA 3 OLS (1.1%) as in SAKURA 1 and 2 (1.0%) and none were related to treatment across the entire SAKURA program

Safety Summary – 2 DaxibotulinumtoxinA for Injection Treatment-related Adverse Events were experienced in fewer treatments (≈14%) in SAKURA 3 OLS across 66 clinical trial sites, compared with the pivotal SAKURA 1 and 2 studies (≈18%) conducted at 30 sites The most frequently occurring treatment-related AEs were headache (4.6% of subjects), injection site pain (3.6%) and injection site erythema (3.0%) and no treatment related SAEs were observed across the entire SAKURA program Progressively lower percentages of subjects experienced treatment-related AEs following successive treatments: Treatment cycle 1 = 16.8%, Treatment cycle 2 = 9.8%, and Treatment cycle 3 = 7.0% Eyelid Ptosis Low rate of eyelid ptosis observed of 0.9% (34 treatment-related events in 3830 treatments), and occurred in 1.3% of subjects at 66 sites. This compares to a rate of 2.2% in 405 subjects treated in SAKURA 1 and 2 Rate decreased with subsequent DAXI treatment cycles: Treatment 1 = 1.0% ; Treatment 2 = 0.8%; Treatment 3 = 0.7% All but one eyelid ptosis was unilateral in presentation; the majority (85%) were mild in severity with a median duration of 44 days

Efficacy Summary DaxibotulinumtoxinA for Injection SAKURA 3 OLS demonstrated efficacy that exceeded or was comparable to that seen in the SAKURA 1 and 2 pivotal studies with DAXI at a dose of 40U. Efficacy of DAXI was highly consistent across successive treatment cycles and multiple endpoints evaluating both response rates and duration of effect. Efficacy results in SAKURA program results represent the highest responder rates and longest duration of effect observed in registration trials for moderate to severe glabellar lines Effectiveness of DAXI was maintained beyond a single treatment with a very high proportion of subjects meeting the treatment goal of None or Mild wrinkle as early as Week 1 None or Mild response rates increased through Week 4 across all 3 treatment cycles to at least 95% of investigators on IGA-FWS and 91% of subjects on PFWS, confirming the robust response observed in SAKURA 1 and 2 Subjects in SAKURA 3 achieved a high ≥2-point composite response rate at week 4 which increased with each successive treatment cycle: Treatment cycle 1 = 73.2%, treatment cycle 2 = 77.7% and treatment cycle 3 = 79.6% SAKURA 3 OLS results confirm the high rate of ≥2-point composite response observed at week 4 in subjects participating in the placebo-controlled SAKURA 1 and 2 studies of 73.6% and 74.0%, respectively

Duration of Effect Summary DaxibotulinumtoxinA for Injection SAKURA OLS results confirm the long duration of clinical benefit observed with the 40U dose of DAXI in SAKURA 1 and 2 and demonstrate consistency across treatment cycles. Median time to return to baseline GL severity was 28 weeks in treatment cycles 1 and 2 and is also consistent with the time taken to loss of complete treatment effect observed in the pivotal SAKURA 1 and 2 studies Median time to loss of none or mild wrinkle severity was 24 weeks in SAKURA 3 OLS treatment cycles 1 and 2 as evaluated by both investigator and subject and identical to duration of clinical benefit observed in SAKURA 1 and 2 Duration of effect in Age and Prior Toxin Exposure subgroups similar or greater than overall SAKURA 3 population, demonstrating predictability and consistency of DAXI in treatment of GL By Age Time to return to baseline wrinkle severity in subjects aged 65 or older was 31 weeks, compared with 28 weeks for subjects less than 65 years and for the overall SAKURA 3 population Subjects aged 65 or greater experienced the same time to loss of none or mild wrinkle severity with a median duration of 24 weeks as those subjects less than 65 years and the overall SAKURA population By Prior Toxin Exposure Median time to return to baseline wrinkle severity was 28 weeks and median time to loss of none or mild wrinkle severity was 24 weeks regardless of prior BoNTA exposure at the time of DAXI treatment

U.S. Neuromodulator Molecular Landscape RT002 and onabotulinumtoxinA have a nearly identical amount of core active ingredient

Commercial-Ready Manufacturing Platform Located in the U.S. US Based Manufacturing for both Drug Substance and Drug Product State-of-the-Art Commercial-ready cGMP facility CMC/Analytics: US Select Agent License Drug Substance Capability to manufacture botulinum neurotoxin type A from 150 kD to 900 kD Drug Product End-to-end drug formulation, filling, lyophilization and packaging

RT002 NEUROSCIENCE Cervical Dystonia Plantar Fasciitis Upper Limb Spasticity Chronic Migraine Preclinical Phase 1 Phase 2 Phase 3 RT002 AESTHETICS Glabellar (Frown) Lines Forehead Lines Lateral Canthal Lines (Crow’s Feet) Expanding Studies of RT002 – Seven in Total New for 2019 New for 2019 File 1H 2019 Launch 2020

Questions?